Related Experiment Videos
Thromboembolic events with lenalidomide-based therapy for multiple myeloma
Smitha Patiyil Menon1, S Vincent Rajkumar, Martha Lacy
1Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.
Cancer
|February 19, 2008
Summary
Lenalidomide therapy for newly diagnosed myeloma showed a lower deep vein thrombosis incidence than expected. High-dose corticosteroids may slightly increase thrombosis risk, warranting further investigation.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Multiple myeloma is a hematologic malignancy.
- Lenalidomide is a key therapeutic agent in multiple myeloma treatment.
- Thromboembolism is a known complication of cancer therapies.
Purpose of the Study:
- To determine the incidence of thromboembolism in newly diagnosed multiple myeloma patients treated with lenalidomide.
- To identify risk factors, including corticosteroid dose and erythropoietin use, associated with thromboembolism.
- To evaluate the effectiveness of thromboprophylaxis in mitigating thromboembolic events.
Main Methods:
- Pooled analysis of 125 patients with previously untreated multiple myeloma from clinical trials.
- Stratification of patients based on concomitant corticosteroid dose (high-dose vs. low-dose).
- Examination of the impact of thromboprophylaxis, including aspirin and erythropoietin supplementation.
Main Results:
- The incidence of deep vein thrombosis was 8% (10 out of 125 patients).
- No significant difference in thromboembolic events was observed between patients receiving erythropoietin and those who did not.
- A trend towards higher venous thrombotic episodes was noted in the high-dose corticosteroid group (12%) compared to the low-dose group (6%), though not statistically significant.
Conclusions:
- The incidence of deep vein thrombosis associated with lenalidomide therapy in this cohort is lower than previously reported.
- High-dose corticosteroid therapy may be associated with a trend towards increased thrombosis risk.
- Further research is warranted to fully elucidate the risk factors and optimal prophylaxis strategies.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...